Vagus Nerve Stimulation: What Helps Depression and What's Hype

You’ve worked through medication after medication, and maybe TMS or ECT too. Meanwhile your feed fills up with ear clips, neck buzzers, and cold plunges that promise to “reset” your vagus nerve. Somewhere in that noise you hear that an implanted vagus nerve stimulator is actually FDA-approved for depression, and it’s hard to tell which of these claims deserves your hope.

Your vagus nerve is a two-way line between your brain and organs like your heart and gut. Medicare’s 2019 decision memo notes that it carries both sensory and motor signals and influences widespread areas of the brain. Implanted VNS uses that wiring with precision. As Medicare’s coverage policy describes it, a pacemaker-like generator under the skin of the left chest sends electrical signals through a wire to the left vagus nerve, and those signals travel on to the brain.

The established path through hard-to-treat depression is sequential: adjust the dose, switch or combine medications, add therapy, and consider ECT or TMS. That path helps many people. In the NIMH-funded STAR*D trial of more than 3,600 outpatients, 37% reached remission on their first treatment, and 31% of those who moved to a second step reached it there. The results are real, and the science is well-established.

But remission rates in that same trial fell to about 13% at the third and fourth steps, and at Siggy we think people who reach that point deserve a clear line between an approved treatment and a gadget borrowing its name.

Implanted VNS is a long-term, add-on treatment that sends regular pulses up the vagus nerve and is thought to shift activity in mood-related brain networks. The FDA approved it in 2005 for adults whose depression hasn’t responded to four or more adequate treatments, and its benefits, when they come, tend to build over a year rather than a few weeks. What separates this implant from an ear clip is the weight of its clinical evidence.

What This Page Covers

• How Does Vagus Nerve Stimulation Work?
• Who Is VNS Approved For?
• What Does the Research Show?
• Implanted VNS vs. Wellness Devices
• What to Expect From Surgery and Side Effects
• Does Insurance Cover VNS for Depression?
• Where VNS Fits Among Your Options
• Get Help Weighing Your Next Step

How Does Vagus Nerve Stimulation Work?

Researchers still don’t know exactly how VNS eases depression. The 2019 Medicare memo describes it as indirect modulation of brain activity, with stimulation of the nerve believed to change brain networks involved in psychiatric illness.

The device is programmable. A clinician sets the current, pulse width, frequency, and on-off cycle with a handheld computer and can adjust them to make stimulation more tolerable or more effective. Holding a magnet over the generator pauses it.

Two very different treatments share the VNS name. Implanted VNS attaches an electrode to the vagus nerve in your neck. Transcutaneous VNS, often called taVNS when it targets the ear, sends a mild current through the skin. In its 2019 review, Medicare noted that these noninvasive devices didn’t have an FDA-approved indication for treatment-resistant depression.

Who Is VNS Approved For?

The FDA’s approval summary from July 2005 limits depression use to adults 18 or older with chronic or recurrent depression who are in a major depressive episode and haven’t had an adequate response to four or more adequate antidepressant treatments. It’s approved as an adjunctive, long-term treatment, which means it’s added to your current care rather than replacing medication or therapy.

The same document lists clear contraindications. VNS can’t be used after surgery that cut the vagus nerve on the left side or both sides of the neck, and people with the device can’t receive certain deep-heating treatments called diathermy.

The studies Medicare covers exclude people with a history of psychotic features, schizophrenia, or rapid-cycling bipolar disorder, along with anyone who has current suicidal intent. People referred for VNS have usually been through a lot. According to a 2026 RECOVER review, participants in that 493-person trial averaged 13.3 lifetime antidepressant treatments and nearly 18 years in their current depressive episode.

What Does the Research Show?

VNS research doesn’t line up neatly behind one conclusion, and you deserve to see all of it.

The Trial Behind the 2005 Approval

In the 10-week sham-controlled trial behind the approval, 15.2% responded to active VNS and 10.0% to sham, a difference that wasn’t statistically significant. The FDA’s approval summary shows the agency relied instead on improvement over one and two years and a comparison with a similar, nonrandomized group receiving usual care.

The Five-Year Registry

Longer follow-up looked more encouraging. A five-year observational registry of 795 people at 61 U.S. sites found cumulative response rates of 67.6% with VNS plus usual care, compared with 40.9% for usual care alone, and first-time remission rates of 43.3% compared with 25.7%. Because patients weren’t randomly assigned and knew which treatment they had, this kind of study can’t rule out other explanations.

What RECOVER Added

The one-year RECOVER trial randomized 493 adults with markedly treatment-resistant depression to active or sham VNS. Its main measure, time spent with at least a 50% drop on one depression rating scale, didn’t separate the groups. Clinician global ratings and patient self-reports did favor active stimulation, and no new safety problems emerged.

The 2026 review adds that function and quality-of-life measures also favored active VNS. Among people who kept using active VNS for a second year, with everyone now aware of their treatment, more than 80% of those with meaningful benefit at 12 months still had it at 18 and 24 months. About 30% of those without benefit at 12 months improved during that second year.

One caution applies throughout. Scientists from LivaNova, the device’s maker, are co-authors on the RECOVER reports, so independent replication still matters.

Implanted VNS vs. Wellness Devices

Search “vagus nerve stimulation” and ear clips, neck devices, and apps show up next to the implant. Under FDA’s wellness guidance, updated in January 2026, the agency doesn’t intend to review low-risk products whose claims stick to things like relaxation or stress management, while a claim to help treat an anxiety disorder falls outside that policy. The guidance states that inclusion under the policy doesn’t establish that a product is safe or effective. It also names a neurostimulation product claiming to improve memory as an example that isn’t low risk, because electrical stimulation carries its own safety risks.

For depression, a 2023 ear-stimulation meta-analysis pooled 12 studies with 838 participants and found lower depression scores, but rated the quality of evidence low to very low. Slow breathing has firmer footing as a self-care skill. In a remote biofeedback meta-analysis, heart rate variability biofeedback, which pairs paced breathing with a heart rate sensor, produced a medium-sized drop in depressive symptoms across 10 studies.

Here’s how those three options compare, based on the sources in this section.

Option	How It Reaches the Nerve	Evidence for Depression
Implanted VNS	Electrode attached to the left vagus nerve	FDA-approved add-on for treatment-resistant depression, mixed sham-controlled results
Ear stimulation (taVNS)	Mild current through the skin of the outer ear	12 trials, low to very low quality evidence
HRV biofeedback	Slow, paced breathing with no electrical current	Medium-sized benefit for depressive symptoms in pooled studies

Breathing and biofeedback can be worthwhile tools for stress and mood, and our guide to nervous system regulation explains how to practice them. Neither one replaces a treatment plan for depression that hasn’t responded to several medications.

What to Expect From Surgery and Side Effects

According to the AANS patient guide, implantation is usually an outpatient procedure that takes 45 to 90 minutes, most often under general anesthesia. A surgeon makes two small incisions, one in the upper left chest and one in the neck, and the brain itself isn’t touched. The stimulator is usually switched on two to four weeks later and turned up gradually. Its battery can last 1 to 15 years, and replacing it means reopening only the chest incision.

Most side effects happen while the device is firing. In the FDA’s review of the pivotal depression trial, 55% of people on active stimulation reported voice changes during the acute phase, compared with 3% on sham, along with increased cough (24%), shortness of breath (19%), and neck pain (16%). Many of these eased over time, though about two-thirds of people with early voice changes still reported them 9 to 12 months later. Medicare’s memo adds surgical risks such as infection in 3 to 6% of patients and vocal cord weakness in about 1%, plus rare heart rhythm problems that mostly occur in the operating room when the device is first tested.

If side effects are hard to live with, the settings can be lowered. Check with your care team before any MRI.

Does Insurance Cover VNS for Depression?

Coverage is often the biggest practical hurdle. Under Medicare’s national coverage policy, VNS for treatment-resistant depression is covered only inside a CMS-approved study: a double-blind, randomized, placebo-controlled trial with at least a year of follow-up, which can extend into a longer-term follow-on study once enrollment is complete and interim results are positive. People who already have a device can get a replacement when the battery runs out or the device malfunctions. As of October 2026, that policy hasn’t changed since it took effect in February 2019.

Private insurers set their own rules. Before you book a surgical consultation, ask your plan for its written medical policy on vagus nerve stimulation and what documentation it requires.

Where VNS Fits Among Your Options

VNS is rarely the next step after one medication stops working. A careful evaluation first checks whether earlier trials were adequate in dose and duration, and options such as augmentation, esketamine, TMS, and ECT are usually weighed before or alongside VNS. Our guide to treatment-resistant depression options walks through them.

VNS tends to make the most sense for people with chronic or recurrent depression who have already tried several of those approaches and want a long-term option layered onto their current care. Because benefit can take a year or more, it also works best with a care team that tracks how you’re doing over time.

Questions to Ask a Specialist

• How many adequate treatment trials have I had, and were the doses and durations enough?
• Which options, such as ECT, TMS, or esketamine, should I try first?
• What improvement should I expect, and over what timeline?
• Who will program the device, and how often will I be seen?
• What will my insurance cover, including battery replacement?
• How will we measure whether it’s working?

If you’re having thoughts of suicide, call or text 988. If you’re in immediate danger, call 911.

This article is for education only and isn’t a substitute for personal medical advice. It reflects sources available as of October 2026.

Get Help Weighing Your Next Step

“No one checks in to see if it’s actually working.” If that sounds familiar, it’s also the opposite of what a slow, long-term treatment like VNS needs. Start your anonymous intake with Siggy to lay out the medications and treatments you’ve tried, what helped, and what didn’t, in your own words. It’s free and asks for no name or email, and you’ll get a downloadable summary to bring to a psychiatrist or brain stimulation specialist. A licensed prescriber reviews every Siggy treatment plan before anything is prescribed. Siggy supports medication care for anxiety and depression and doesn’t provide VNS, so the device decision stays with a specialist who offers it.